Aripipratsoli Adhd

https://biotechreporter.news › recursion-nasdaqrxrx-reports-pipeline...
Recursion is maintaining its 2026 guidance of less than 390 million in operational cash burn which is expected to

https://trendonify.com › news › sec-filings
RECURSION PHARMACEUTICALS RXRX announced its financial results and business updates for the first quarter

https://www.chartmill.com › news › RXRX
Recursion Pharmaceuticals RXRX Q1 2026 net loss of 0 22 beat estimates but revenue of 6 5M missed the

https://www.biospace.com › press-releases › recursion-reports-first...
Cash Position Cash cash equivalents and restricted cash were 665 2 million as of March 31 2026 compared to

https://www.stocktitan.net › news › RXRX › recursion-reports-first-quarter...
Recursion reported 665 2 million in cash cash equivalents and restricted cash as of March 31 2026 According to the company

https://finsee.ai › earnings › rxrx › en
With the REC 1245 cancer program showing clean early safety data and REC 4881 heading to FDA registrational

https://www.allinvestview.com › earnings › RXRX
Operating expenses reduced by 30 year over year extending financial runway into early 2028 indicating ongoing

https://www.msn.com › en-us › money › economy
The company reiterated a cash runway into early 2028 without additional financing maintained 2026 cash operating

https://www.investing.com › news › transcripts › earnings-call-transcript...
The company achieved a 30 reduction in cash operating expenses year over year and it closed the quarter with